Modular Medical Inc. Receives IRB Approval for Feasibility Study of Next-Gen Pivot Insulin Delivery System

Reuters

09/15

Modular Medical Inc. Receives IRB Approval for Feasibility Study of Next-Gen Pivot Insulin Delivery System

Modular Medical Inc., a leader in innovative insulin delivery technology, announced that it has received Institutional Review Board (IRB) approval to conduct an in-house feasibility study of its next-generation Pivot insulin delivery system. The study will evaluate the usability and extended wear of the tubeless patch pump using sterile saline on adult participants over a period of up to 90 days. This approval is a crucial step toward refining the Pivot pump before its anticipated 510(k) submission to the FDA in October 2025. The study aims to identify challenges in prolonged wear, gather participant feedback, and support regulatory pathways to potentially unlock new markets. The Pivot pump is not yet cleared for sale by the FDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modular Medical Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073041) on September 15, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2567197281"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567197281\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567197281?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-15 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567197281","market":"nz","top_or_hot":-1,"title":"Modular Medical Inc. Receives IRB Approval for Feasibility Study of Next-Gen Pivot Insulin Delivery System","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Modular Medical Inc. Receives IRB Approval for Feasibility Study of Next-Gen Pivot Insulin Delivery System\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Modular Medical Inc., a leader in innovative insulin delivery technology, announced that it has received Institutional Review Board (IRB) approval to conduct an in-house feasibility study of its next-generation Pivot insulin delivery system. The study will evaluate the usability and extended wear of the tubeless patch pump using sterile saline on adult participants over a period of up to 90 days. This approval is a crucial step toward refining the Pivot pump before its anticipated 510(k) submission to the FDA in October 2025. The study aims to identify challenges in prolonged wear, gather participant feedback, and support regulatory pathways to potentially unlock new markets. The Pivot pump is not yet cleared for sale by the FDA.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modular Medical Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073041) on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Modular Medical Inc. Receives IRB Approval for Feasibility Study of Next-Gen Pivot Insulin Delivery System</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModular Medical Inc. Receives IRB Approval for Feasibility Study of Next-Gen Pivot Insulin Delivery System\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-15 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Modular Medical Inc. Receives IRB Approval for Feasibility Study of Next-Gen Pivot Insulin Delivery System\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Modular Medical Inc., a leader in innovative insulin delivery technology, announced that it has received Institutional Review Board (IRB) approval to conduct an in-house feasibility study of its next-generation Pivot insulin delivery system. The study will evaluate the usability and extended wear of the tubeless patch pump using sterile saline on adult participants over a period of up to 90 days. This approval is a crucial step toward refining the Pivot pump before its anticipated 510(k) submission to the FDA in October 2025. The study aims to identify challenges in prolonged wear, gather participant feedback, and support regulatory pathways to potentially unlock new markets. The Pivot pump is not yet cleared for sale by the FDA.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modular Medical Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073041) on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL15JLMr:1","article_id":"2567197281","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567197281","pubTimestamp":1757937671,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Modular Medical Inc., a leader in innovative insulin delivery technology, announced that it has received Institutional Review Board  approval to conduct an in-house feasibility study of its next-generation Pivot insulin delivery system. The study will evaluate the usability and extended wear of the tubeless patch pump using sterile saline on adult participants over a period of up to 90 days. This approval is a crucial step toward refining the Pivot pump before its anticipated 510 submission to the FDA in October 2025. The study aims to identify challenges in prolonged wear, gather participant feedback, and support regulatory pathways to potentially unlock new markets. The Pivot pump is not yet cleared for sale by the FDA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","MODD":"Modular Medical, Inc."},"translate_title":"Modular Medical Inc.下一代Pivot胰岛素输送系统可行性研究获得IRB批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MODD":0.9},"content_text":"Modular Medical Inc. Receives IRB Approval for Feasibility Study of Next-Gen Pivot Insulin Delivery System\n    \n\n        Modular Medical Inc., a leader in innovative insulin delivery technology, announced that it has received Institutional Review Board (IRB) approval to conduct an in-house feasibility study of its next-generation Pivot insulin delivery system. The study will evaluate the usability and extended wear of the tubeless patch pump using sterile saline on adult participants over a period of up to 90 days. This approval is a crucial step toward refining the Pivot pump before its anticipated 510(k) submission to the FDA in October 2025. The study aims to identify challenges in prolonged wear, gather participant feedback, and support regulatory pathways to potentially unlock new markets. The Pivot pump is not yet cleared for sale by the FDA.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modular Medical Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073041) on September 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}